Shenzhen Kangtai Biological Products Co., Ltd.
Символ: 300601.SZ
SHZ
22.57
CNYПазарна цена днес
64.1644
Съотношение P/E
0.4968
Коефициент PEG
24.02B
MRK Cap
- 0.01%
Доходност на DIV
Shenzhen Kangtai Biological Products Co., Ltd. (300601-SZ) финансови отчети
Баланс
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 4273.3 | 1458.4 | 3549.5 | 3037.8 | |||||||||||
balance-sheet.row.short-term-investments | 495.13 | 440.8 | 725.6 | 2155.1 | |||||||||||
balance-sheet.row.net-receivables | 10524.6 | 2414.7 | 1991.2 | 1765.7 | |||||||||||
balance-sheet.row.inventory | 3187.42 | 727.8 | 1058.2 | 436.5 | |||||||||||
balance-sheet.row.other-current-assets | 3168.45 | 573.9 | 741.7 | 104.4 | |||||||||||
balance-sheet.row.total-current-assets | 21153.76 | 5174.9 | 7340.7 | 5344.6 | |||||||||||
balance-sheet.row.property-plant-equipment-net | 21809.47 | 5176.1 | 4116.4 | 2279.1 | |||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.intangible-assets | 1963.32 | 475.2 | 736.3 | 367.4 | |||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 1963.32 | 475.2 | 736.3 | 367.4 | |||||||||||
balance-sheet.row.long-term-investments | 2234.28 | 2041.3 | 99.4 | 122.6 | |||||||||||
balance-sheet.row.tax-assets | 2664.31 | 708.3 | 558.6 | 702 | |||||||||||
balance-sheet.row.other-non-current-assets | 6774.33 | 210.6 | 1297.6 | 768.8 | |||||||||||
balance-sheet.row.total-non-current-assets | 35445.71 | 8611.5 | 6808.3 | 4239.9 | |||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.total-assets | 56599.47 | 13786.4 | 14149 | 9584.5 | |||||||||||
balance-sheet.row.account-payables | 2110.73 | 434.1 | 708.2 | 167.4 | |||||||||||
balance-sheet.row.short-term-debt | 1009.99 | 273.7 | 800.1 | 23.4 | |||||||||||
balance-sheet.row.tax-payables | 234.81 | 173.4 | 98.2 | 678.5 | |||||||||||
balance-sheet.row.long-term-debt-total | 8432.24 | 2015.7 | 1938 | 67.8 | |||||||||||
Deferred Revenue Non Current | 1445.95 | 383.1 | 349.5 | 278.5 | |||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 100.9 | - | - | - | |||||||||||
balance-sheet.row.other-current-liab | 3057.34 | 1600.8 | 2.8 | 0 | |||||||||||
balance-sheet.row.total-non-current-liabilities | 10106.81 | 2461.2 | 2364.1 | 365.1 | |||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.total-liab | 19554.29 | 4801 | 4982.2 | 2121.1 | |||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.common-stock | 4471.23 | 1120.5 | 687.1 | 684.9 | |||||||||||
balance-sheet.row.retained-earnings | 7977.3 | 1641.1 | 2435 | 1397.9 | |||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 18318.51 | 3036 | 2417.5 | 1753.6 | |||||||||||
balance-sheet.row.other-total-stockholders-equity | 6278.14 | 3187.7 | 3627.1 | 3627 | |||||||||||
balance-sheet.row.total-stockholders-equity | 37045.18 | 8985.3 | 9166.7 | 7463.4 | |||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 56599.47 | 13786.4 | 14149 | 9584.5 | |||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.total-equity | 37045.18 | 8985.3 | 9166.7 | 7463.4 | |||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 56599.47 | - | - | - | |||||||||||
Total Investments | 495.13 | 440.8 | 99.4 | 2155.1 | |||||||||||
balance-sheet.row.total-debt | 9442.23 | 2289.4 | 2738.1 | 91.2 | |||||||||||
balance-sheet.row.net-debt | 5664.06 | 1271.7 | -811.4 | -791.5 |
Отчет за паричните потоци
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 361.2 | -132.7 | 1263.4 | 679.2 | |||||||||||
cash-flows.row.depreciation-and-amortization | 73.78 | 200.9 | 404.7 | 92.9 | |||||||||||
cash-flows.row.deferred-income-tax | -175.09 | -205.5 | 50.7 | 93.2 | |||||||||||
cash-flows.row.stock-based-compensation | 13.16 | 10 | 30 | 104.8 | |||||||||||
cash-flows.row.change-in-working-capital | -268.01 | -604.5 | -275.6 | -461.7 | |||||||||||
cash-flows.row.account-receivables | -488.76 | -488.8 | 273.9 | -796.5 | |||||||||||
cash-flows.row.inventory | 220.75 | 220.7 | -746.7 | -209.7 | |||||||||||
cash-flows.row.account-payables | -9.97 | -131 | 146.5 | 451.3 | |||||||||||
cash-flows.row.other-working-capital | 9.97 | -205.5 | 50.7 | 93.2 | |||||||||||
cash-flows.row.other-non-cash-items | 364.95 | 1277.6 | 179.2 | -68.6 | |||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 366.78 | 0 | 0 | 0 | |||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -790.02 | -1310.4 | -2540.4 | -1226.7 | |||||||||||
cash-flows.row.acquisitions-net | 0.45 | 0.1 | 0.2 | 1227.7 | |||||||||||
cash-flows.row.purchases-of-investments | -3810 | -3518 | -1100 | -2625 | |||||||||||
cash-flows.row.sales-maturities-of-investments | 2951.88 | 2224.4 | 2198.2 | 13.7 | |||||||||||
cash-flows.row.other-investing-activites | 820.5 | -2.4 | 1.7 | -1226.7 | |||||||||||
cash-flows.row.net-cash-used-for-investing-activites | -827.19 | -2606.3 | -1440.3 | -3836.9 | |||||||||||
cash-flows.row.debt-repayment | -392.33 | -1070.4 | -26.5 | -256 | |||||||||||
cash-flows.row.common-stock-issued | 233.69 | 132.7 | -2.1 | -1 | |||||||||||
cash-flows.row.common-stock-repurchased | -121.54 | -20.6 | 2.1 | -0.2 | |||||||||||
cash-flows.row.dividends-paid | -35.25 | -622.2 | -220.4 | -207.3 | |||||||||||
cash-flows.row.other-financing-activites | 41.81 | 1115.6 | 2699 | 4243.3 | |||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | -273.62 | -464.9 | 2452.2 | 3778.7 | |||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0.05 | -1.7 | -1 | 0 | |||||||||||
cash-flows.row.net-change-in-cash | -190.12 | -2527.1 | 2663.1 | 381.6 | |||||||||||
cash-flows.row.cash-at-end-of-period | 3684.72 | 994.1 | 3521.3 | 858.1 | |||||||||||
cash-flows.row.cash-at-beginning-of-period | 3874.84 | 3521.3 | 858.1 | 476.5 | |||||||||||
cash-flows.row.operating-cash-flow | 366.78 | 545.7 | 1652.3 | 439.8 | |||||||||||
cash-flows.row.capital-expenditure | -790.02 | -1310.4 | -2540.4 | -1226.7 | |||||||||||
cash-flows.row.free-cash-flow | -423.24 | -764.7 | -888.1 | -786.8 |
Ред за отчет за приходите
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 3056.8 | 3157.4 | 3652.1 | 2261.2 | |||||||||||
income-statement-row.row.cost-of-revenue | 510.9 | 499.9 | 986.4 | 226.3 | |||||||||||
income-statement-row.row.gross-profit | 2545.9 | 2657.5 | 2665.7 | 2034.9 | |||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.research-development | 579.47 | - | - | - | |||||||||||
income-statement-row.row.selling-general-administrative | 42.63 | - | - | - | |||||||||||
income-statement-row.row.selling-and-marketing-expenses | 1045.21 | - | - | - | |||||||||||
income-statement-row.row.other-expenses | 120.13 | 74.4 | 73.9 | 110.5 | |||||||||||
income-statement-row.row.operating-expenses | 1700.95 | 2020.8 | 1071.9 | 1291.4 | |||||||||||
income-statement-row.row.cost-and-expenses | 2211.85 | 2520.8 | 2058.4 | 1517.7 | |||||||||||
income-statement-row.row.interest-income | 151.88 | 132.6 | 114.9 | 24.1 | |||||||||||
income-statement-row.row.interest-expense | 111.92 | 109 | 54.5 | 2.3 | |||||||||||
income-statement-row.row.selling-and-marketing-expenses | 1045.21 | - | - | - | |||||||||||
income-statement-row.row.total-other-income-expensenet | -15.11 | -1085.3 | -13 | -3 | |||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||
income-statement-row.row.other-operating-expenses | 120.13 | 74.4 | 73.9 | 110.5 | |||||||||||
income-statement-row.row.total-operating-expenses | -15.11 | -1085.3 | -13 | -3 | |||||||||||
income-statement-row.row.interest-expense | 111.92 | 109 | 54.5 | 2.3 | |||||||||||
income-statement-row.row.depreciation-and-amortization | 647.17 | 200.9 | 676.6 | 95.5 | |||||||||||
income-statement-row.row.ebitda-caps | 945.76 | - | - | - | |||||||||||
income-statement-row.row.operating-income | 298.59 | 747 | 1452.2 | 775.4 | |||||||||||
income-statement-row.row.income-before-tax | 283.48 | -338.2 | 1439.2 | 772.4 | |||||||||||
income-statement-row.row.income-tax-expense | -77.71 | -205.5 | 175.9 | 93.2 | |||||||||||
income-statement-row.row.net-income | 361.2 | -132.7 | 1263.4 | 679.2 |
Често задавани въпроси
Какво е Shenzhen Kangtai Biological Products Co., Ltd. (300601.SZ) общи активи?
Shenzhen Kangtai Biological Products Co., Ltd. (300601.SZ) общите активи са 13786351671.000.
Какъв е годишният приход на предприятието?
Годишните приходи са 1716081476.000.
Какъв е маржът на печалбата на предприятието?
Маржът на печалбата на фирмата е -0.379.
Какъв е свободният паричен поток на компанията?
Свободният паричен поток е -0.379.
Какъв е маржът на нетната печалба на предприятието?
Маржът на нетната печалба е 0.118.
Какъв е общият приход на предприятието?
Общият приход е 0.098.
Каква е Shenzhen Kangtai Biological Products Co., Ltd. (300601.SZ) нетна печалба (нетен доход)?
Нетната печалба (нетният доход) е -132707859.290.
Какъв е общият дълг на фирмата?
Общият дълг е 2289363332.000.
Какъв е броят на оперативните разходи?
Оперативните разходи са 2020824155.000.
Какъв е броят на паричните средства на фирмата?
Паричните средства на предприятието са 1032022400.000.